uHD: Unary Processing for Lightweight and Dynamic Hyperdimensional Computing

Hyperdimensional computing (HDC) is a novel computational paradigm that operates on long-dimensional vectors known as hypervectors. The hypervectors are constructed as long bit-streams and form the basic building blocks of HDC systems. In HDC, hypervectors are generated from scalar values without taking their bit significance into consideration. HDC has been shown to be efficient and robust in various data processing applications, including computer vision tasks. To construct HDC models for vision applications, the current state-of-the-art practice utilizes two parameters for data encoding: pixel intensity and pixel position. However, the intensity and position information embedded in high-dimensional vectors are generally not generated dynamically in the HDC models. Consequently, the optimal design of hypervectors with high model accuracy requires powerful computing platforms for training. A more efficient approach to generating hypervectors is to create them dynamically during the training phase, which results in accurate, low-cost, and highly performable vectors. To this aim, we use low-discrepancy sequences to generate intensity hypervectors only, while avoiding position hypervectors. By doing so, the multiplication step in vector encoding is eliminated, resulting in a power-efficient HDC system. For the first time in the literature, our proposed approach employs lightweight vector generators utilizing unary bit-streams for efficient encoding of data instead of using conventional comparator-based generators.Comment: 7 pages, 6 figures, Accepted to the Design, Automation and Test in Europe (DATE) Conference 202

Modified artificial diet for rearing of tobacco budworm, Helicoverpa armigera using the Taguchi method and Derringer’s desirability function

With the aim to improve the mass rearing feasibility of tobacco budworm, Helicoverpa armigera Hübner (Lepidoptera: Noctuidae), design of experimental methodology using Taguchi orthogonal array was applied. To do so, the effect of 16 ingredients of an artificial diet including bean, wheat germ powder, Nipagin, ascorbic acid, formaldehyde, oil, agar, distilled water, ascorbate, yeast, chloramphenicol, benomyl, penicillin, temperature, humidity, and container size on some biological characteristics of H. armigera was evaluated. The selected 16 factors were considered at two levels (32 experiments) in the experimental design. Among the selected factors, penicillin, container size, formaldehyde, chloramphenicol, wheat germ powder, and agar showed significant effect on the mass rearing performance. Derringer's desirability function was used for simultaneous optimization of mass rearing of tobacco budworm, H. armigera, on a modified artificial diet. Derived optimum operating conditions obtained by Derringer's desirability function and Taguchi methodology decreased larval period from 19 to 15.5 days (18.42 % improvement), decreased the pupal period from 12.29 to 11 days (10.49 % improvement), increased the longevity of adults from 14.51 to 21 days (44.72 % improvement), increased the number of eggs/female from 211.21 to 260, and increased egg hatchability from 54.2% to 72% (32.84 % improvement). The proposed method facilitated a systematic mathematical approach with a few well-defined experimental sets

Antimicrobial peptides of the vaginal innate immunity and their role in the fight against sexually transmitted diseases

Some antimicrobial peptides (AMPs) are produced in the vaginal innate immune system and play an important role in protecting this organ against pathogenic agents. Moreover, sexually transmitted diseases have become a major problem in human societies and are rapidly spreading. The emergence of antibiotic-resistant microbes (superbugs) can pose a major threat to human societies and cause rapid spread of these diseases. Finding new antimicrobial compounds to fight superbugs is therefore essential. It has been shown that AMPs have good potential to become new antibiotics. The most important AMPs in the vaginal innate immune system are defensins, secretory leucocyte protease inhibitors, calprotectin, lysozyme, lactoferrin and elafin, which play an important role in host defence against sexually transmitted infections, modulation of immune responses and anticancer activities. Some AMPs, such as LL-37, magainin 2 and nisin, show both spermicidal and antimicrobial effects in the vagina. In this summary, we will discuss vaginal AMPs and continue to address some of the challenges of using peptides to control pathogens that are effective in sexually transmitted diseases. © 2019 The Author(s

Seasonal variation in the characteristics of the Azarbaijani buffalo (Bubalus bubalis) semen

Summary To study the seasonal variation in the characteristics of the Azarbaijani buffalo semen, three 2-4-year-old bulls of Azarbaijani water buffaloes, kept in the Buffalo Breeding Center, in Urmia, northwest of Iran, were selected. Semen samples were collected once a week for a period of one year using artificial vagina and a buffalo cow as a dummy. Semen volume, colour, pH and motility and spermatozoa motility, viability, morphology and concentration were examined. During one calendar year, 129 semen samples were examined. The mean values were plotted and a curve was drawn for the annual variations in each parameter. The comparison of the mean values in each sampling and in different seasons and the correlation between these variations and ecological factors, such as temperature, rainfall and day length were also studied. Semen was characterized by a mean (±SEM) ejaculation volume of 4 ± 0.14 ml, semen colour density score of 3.75 ± 0.07, pH of 6.97 ± 0.03 and motility score of 2.89 ± 0.05. The sperm motility of 75.85% ± 1.59% and sperm viability of 73.2% ± 1.56% were observed; 11.55% ± 0.42% of spermatozoa had abnoraml morphology. The mean (±SEM) sperm concentration was 1239.9 ± 34.11×10 6 cells/ml. All of the studied parameters showed fluctuations throughout the year but these variations were statistically significant only in some occasions and were mostly correlated with length of the day. Semen of better quality was collected in summer and autumn

Study of the Effects of Acidic Ions on Cloud Droplet Formation Using Laboratory Experiments

AbstractAtmospheric aerosols affect climate of the Earth, scatter sunlight and serve as cloud condensation nuclei (CCN). Yet the reason for many observed events of new aerosol formation is not understood. One of the ideas put forward to explain these events is that the presence of SO42- can enhance the formation of aerosols. These sulphate aerosols form partly during the oxidation of the oceanic emission Dimethyl sulfide (DMS) into the atmosphere and partly from volcanoes, plants and soils, fossil fuel combustion, and biomass burning. In this paper, laboratory experiments on warm cloud formation with different acid ion density are presented. The results show that the lifetime of cloud is reduced by increasing density of SO42-, but this changes is not significant (significance level, P=0.578), while the cloud concentration is significantly changed with the decreasing of density of SO42- (P=0.001). There is also a good significant correlation between cloud concentration with the maximum temperature change, with correlation coefficient, r=0.646 (p=0.004)

P2LSG: Powers-of-2 Low-Discrepancy Sequence Generator for Stochastic Computing

Stochastic Computing (SC) is an unconventional computing paradigm processing data in the form of random bit-streams. The accuracy and energy efficiency of SC systems highly depend on the stochastic number generator (SNG) unit that converts the data from conventional binary to stochastic bit-streams. Recent work has shown significant improvement in the efficiency of SC systems by employing low-discrepancy (LD) sequences such as Sobol and Halton sequences in the SNG unit. Still, the usage of many well-known random sequences for SC remains unexplored. This work studies some new random sequences for potential application in SC. Our design space exploration proposes a promising random number generator for accurate and energy-efficient SC. We propose P2LSG, a low-cost and energy-efficient Low-discrepancy Sequence Generator derived from Powers-of-2 VDC (Van der Corput) sequences. We evaluate the performance of our novel bit-stream generator for two SC image and video processing case studies: image scaling and scene merging. For the scene merging task, we propose a novel SC design for the first time. Our experimental results show higher accuracy and lower hardware cost and energy consumption compared to the state-of-the-art.Comment: 7 pages, 7 figures, Accepted in 29th ASP-DAC 2024 Conferenc

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

Ipilimumab is a first-in-class immunological checkpoint blockade agent and monoclonal antibody against Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) that has demonstrated survival benefit and durable responses in patients with metastatic melanoma. To date, solid organ transplant recipients have been excluded from clinical trials with cancer immunotherapies on the basis of their concurrent treatment with immunosuppressive agents. We present the first case to our knowledge of a patient with advanced cutaneous melanoma receiving ipilimumab status post orthotopic liver transplantation with a partial response. Transaminitis was observed 4 months after administration of ipilimumab that resolved with close observation. No evidence of graft rejection has been observed to date. This case advocates for further investigation of the safety and efficacy of cancer immunotherapies in solid organ transplant recipients

546 Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

BackgroundTebe, a T cell receptor fused to an anti-CD3 effector, can redirect T cells to target gp100+ cells and in Ph3, demonstrated overall survival (OS) benefit as monotherapy in metastatic uveal melanoma. In Ph2, any tumor shrinkage (44% of patients) was a better predictor of OS than response rate. In Ph1, Tebe had monotherapy activity in mCM, also a gp100+ tumor, with 1-year OS ~74% in PD-1 naïve mCM. A Ph1 dose escalation of tebe with durva (anti-PD-L1) and/or treme (anti-CTLA4) was conducted in pre-treated mCM [NCT02535078], with nearly all patients having prior PD1-treatment, and where recently reported therapies have 1-yr OS of ~55%.MethodsHeavily pre-treated HLA-A2+ mCM patients received weekly IV tebe alone (Arm 4) or with increasing doses of durva and/or treme (Arm 1–3) administered IV monthly starting day 15 of each cycle. Primary objective was to identify RP2D of combination therapy. Secondary objectives included adverse events (AE) and efficacy.Results112 pts received ≥1 tebe dose. Median age was 59, 77% were ECOG 0, and 37% were BRAFm (of which 71% received prior BRAFi/MEKi). 91% of pts were 2L+, while 74% were 3L+. 103 (92%) received prior PD-1 inhibitor, of which 87% also received prior ipilimumab. 43 pts received tebe + durva (Arm 1), 13 received tebe + treme (Arm 2), 29 received triplet therapy (Arm 3), and 27 received tebe alone (Arm 4). Maximum target doses of tebe (68 mcg) + durva (20 mg/kg) and treme (1 mg/kg) were tolerated. MTD was not formally identified for any arm. Two DLTs occurred: prolonged grade 3 rash (Arm 1) and grade 2 diarrhea leading to treatment delay (Arm 2). Related AEs that were Grade ≥3 or led to discontinuations were: 44%/0% (Arm 1), 23%/0% (Arm2), 38%/7% (Arm3), 26%/4% (Arm 4). There were no treatment-related deaths.In prior PD-1 pts, tumor shrinkage occurred in 36% and 1-yr OS was 68%. Of 51 evaluable PD-1 resistant pts (best response CR/PR/SD to prior PD1), tumor shrinkage occurred in 28% and 1-yr OS was 73% (figure 1). In 35 evaluable PD-1 refractory pts (prior best response PD), tumor shrinkage occurred in 49% and 1-yr OS was 61%. For 38 prior PD-1 pts who received ≥10mg/kg durva, 1-yr OS was 81%.Abstract 546 Figure 1% tumor change from baseline in evaluable patients with known response to prior PD1 exposureConclusionsTebe with anti-PD-L1 and/or anti-CTLA4 had an acceptable safety profile. Tebe + durva demonstrated durable tumor shrinkage and promising 1-yr OS rates in prior-PD1 treated mCM relative to recent reports.Trial RegistrationNCT02535078Ethics ApprovalThe institutional review board or independent ethics committee at each center approved the trial. The trial was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines

Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicentre, randomised trial (SUMIT)

Purpose: Uveal melanoma is the most common primary intraocular malignancy in adults with no effective systemic treatment option in the metastatic setting. Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent activity in patients with metastatic uveal melanoma in a randomized phase II trial. Methods: The Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT) study was a phase III, double-blind trial (ClinicalTrial.gov identifier: NCT01974752) in which patients with metastatic uveal melanoma and no prior systemic therapy were randomly assigned (3:1) to selumetinib (75 mg twice daily) plus dacarbazine (1,000 mg/m2 intravenously on day 1 of every 21- day cycle) or placebo plus dacarbazine. The primary end point was progression-free survival (PFS) by blinded independent central radiologic review. Secondary end points included overall survival and objective response rate. Results: A total of 129 patients were randomly assigned to receive selumetinib plus dacarbazine (n = 97) or placebo plus dacarbazine (n = 32). In the selumetinib plus dacarbazine group, 82 patients (85%) experienced a PFS event, compared with 24 (75%) in the placebo plus dacarbazine group (median, 2.8 v 1.8 months); the hazard ratio for PFS was 0.78 (95% CI, 0.48 to 1.27; two-sided P = .32). The objective response rate was 3% with selumetinib plus dacarbazine and 0% with placebo plus dacarbazine (two-sided P = .36). At 37% maturity (n = 48 deaths), analysis of overall survival gave a hazard ratio of 0.75 (95% CI, 0.39 to 1.46; two-sided P = .40). The most frequently reported adverse events (selumetinib plus dacarbazine v placebo plus dacarbazine) were nausea (62% v 19%), rash (57% v 6%), fatigue (44% v 47%), diarrhea (44% v 22%), and peripheral edema (43% v 6%). Conclusion: In patients with metastatic uveal melanoma, the combination of selumetinib plus dacarbazine had a tolerable safety profile but did not significantly improve PFS compared with placebo plus dacarbazine